生物仿制药-话题@MedSci

#生物仿制药#

69篇内容 | 2526人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1412933, encodeId=1a1b1412933aa, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, objectType=article, longId=167495, objectId=7c2016e4958b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2016e4958b, replyNumber=0, likeNumber=67, createdTime=2019-06-03, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2016e4958b, moduleTitle=欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c2016e4958b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412932, encodeId=245e1412932ac, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, objectType=article, longId=166718, objectId=55b4166e1844, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55b4166e1844, replyNumber=0, likeNumber=85, createdTime=2019-05-25, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55b4166e1844, moduleTitle=加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55b4166e1844)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412931, encodeId=67dd14129318c, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=2019 临床建议：接受生物仿制药治疗的IBD患者反安慰剂效应的预防和管理, objectType=article, longId=164920, objectId=3b2d16492015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b2d16492015, replyNumber=0, likeNumber=65, createdTime=2019-04-25, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b2d16492015, moduleTitle=2019 临床建议：接受生物仿制药治疗的IBD患者反安慰剂效应的预防和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b2d16492015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412930, encodeId=21dd141293065, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=2019 PANLAR共识声明：生物仿制药, objectType=article, longId=164368, objectId=d8a61643685e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8a61643685e, replyNumber=0, likeNumber=61, createdTime=2019-04-17, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8a61643685e, moduleTitle=2019 PANLAR共识声明：生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8a61643685e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412929, encodeId=ad5114129293e, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功, objectType=article, longId=162030, objectId=356d1620300f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356d1620300f, replyNumber=0, likeNumber=52, createdTime=2019-03-12, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356d1620300f, moduleTitle=Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=356d1620300f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412928, encodeId=c68414129281e, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症, objectType=article, longId=161663, objectId=6e94161663bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e94161663bc, replyNumber=0, likeNumber=74, createdTime=2019-03-06, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e94161663bc, moduleTitle=Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e94161663bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412927, encodeId=07d8141292e74, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=便宜又好用的肿瘤生物仿制药，你了解有多少？, objectType=article, longId=161238, objectId=ebcb16123867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebcb16123867, replyNumber=0, likeNumber=75, createdTime=2019-02-28, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebcb16123867, moduleTitle=便宜又好用的肿瘤生物仿制药，你了解有多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebcb16123867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412926, encodeId=fbf2141292600, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, objectType=article, longId=160659, objectId=32b11606595c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b11606595c, replyNumber=0, likeNumber=65, createdTime=2019-02-22, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b11606595c, moduleTitle=辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b11606595c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412925, encodeId=ead11412925fc, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, objectType=article, longId=159211, objectId=6a41159211ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a41159211ca, replyNumber=0, likeNumber=60, createdTime=2019-01-31, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a41159211ca, moduleTitle=Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a41159211ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412924, encodeId=afa2141292426, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Inflam Bowel Dis：炎症性肠病患者从单抗治疗药物转换为生物仿制药CT-P13后的药物存活和免疫原性, objectType=article, longId=157182, objectId=d67915e182c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d67915e182c6, replyNumber=0, likeNumber=63, createdTime=2019-01-03, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d67915e182c6, moduleTitle=Inflam Bowel Dis：炎症性肠病患者从单抗治疗药物转换为生物仿制药CT-P13后的药物存活和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d67915e182c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412923, encodeId=3c581412923c0, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果, objectType=article, longId=153505, objectId=e6e515350516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e515350516, replyNumber=0, likeNumber=67, createdTime=2018-11-16, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e515350516, moduleTitle=Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6e515350516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412922, encodeId=7702141292251, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）, objectType=article, longId=148315, objectId=4743148315b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4743148315b5, replyNumber=0, likeNumber=0, createdTime=2018-09-07, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4743148315b5, moduleTitle=2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4743148315b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412921, encodeId=157d141292138, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Clover制药在中国启动依那西普生物仿制药的I期试验, objectType=article, longId=145739, objectId=a66f145e39d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66f145e39d1, replyNumber=0, likeNumber=75, createdTime=2018-08-04, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66f145e39d1, moduleTitle=Clover制药在中国启动依那西普生物仿制药的I期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66f145e39d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412920, encodeId=66ad14129203b, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准, objectType=article, longId=145635, objectId=848014563563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=848014563563, replyNumber=0, likeNumber=69, createdTime=2018-08-03, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=848014563563, moduleTitle=辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=848014563563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412919, encodeId=58f014129195e, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Sandoz获得欧洲委员会对生物仿制药Hyrimoz的批准, objectType=article, longId=145409, objectId=aba8145409dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aba8145409dd, replyNumber=0, likeNumber=76, createdTime=2018-07-30, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aba8145409dd, moduleTitle=Sandoz获得欧洲委员会对生物仿制药Hyrimoz的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aba8145409dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412918, encodeId=a3af141291876, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=EMA支持批准Amgen的Neulasta的第一个生物仿制药版本, objectType=article, longId=145379, objectId=2d8b1453e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8b1453e9a0, replyNumber=0, likeNumber=64, createdTime=2018-07-30, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8b1453e9a0, moduleTitle=EMA支持批准Amgen的Neulasta的第一个生物仿制药版本, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d8b1453e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412917, encodeId=740a141291e97, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症, objectType=article, longId=145075, objectId=ca0b1450e5d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca0b1450e5d7, replyNumber=0, likeNumber=64, createdTime=2018-07-25, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca0b1450e5d7, moduleTitle=辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca0b1450e5d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412916, encodeId=7ab814129165c, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素, objectType=article, longId=145029, objectId=be031450298b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be031450298b, replyNumber=0, likeNumber=59, createdTime=2018-07-25, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be031450298b, moduleTitle=Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be031450298b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412915, encodeId=6d36141291576, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=56, createdTime=2018-06-30, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412914, encodeId=dc171412914d4, content=<a href='/topic/show?id=a3996918811' target=_blank style='color:#2F92EE;'>#生物仿制药#</a>, objectTitle=欧盟通过Sandoz的Remicade生物仿制药Zessly, objectType=article, longId=139097, objectId=b7a513909e06, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7a513909e06, replyNumber=0, likeNumber=76, createdTime=2018-05-26, rootId=0, userName=grace5701, userId=cfb42911806, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7a513909e06, moduleTitle=欧盟通过Sandoz的Remicade生物仿制药Zessly, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7a513909e06)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

生物仿制药

2020-05-29

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

欧洲药品管理局（EMA）接受曲妥珠单抗生物仿制药营销授权申请

2019-06-03

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

加拿大卫生部批准**款曲妥珠单抗生物仿制药Ogivri用于治疗HER2阳性的乳腺癌和胃癌

2019-05-25

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

2019 临床建议：接受生物仿制药治疗的IBD患者反安慰剂效应的预防和管理

2019-04-25

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

2019 PANLAR共识声明：生物仿制药

2019-04-17

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功

2019-03-12

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Napp在英国推出了pegfilgrastim的生物仿制药治疗中性粒细胞减少症

2019-03-06

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

便宜又好用的肿瘤生物仿制药，你了解有多少？

2019-02-28

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

辉瑞的Avastin生物仿制药——ZIRABEV在欧洲获批治疗多个转移性肿瘤

2019-02-22

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Coherus宣布与AbbVie达成全球和解，确保其Adalimumab生物仿制药CHS-1420商业化的权利

2019-01-31

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Inflam Bowel Dis：炎症性肠病患者从单抗治疗药物转换为生物仿制药CT-P13后的药物存活和免疫原性

2019-01-03

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Ann Rheum Dis：换药或不换药？从初始药强制换为依那西普生物仿制药全国性指南的结果

2018-11-16

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

2018 ESPGHAN立场声明：生物仿制药在儿童炎症性肠病患者中的应用（更新版）

2018-09-07

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Clover制药在中国启动依那西普生物仿制药的I期试验

2018-08-04

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

辉瑞Trazimera（Herceptin生物仿制药）已获欧盟委员会的批准

2018-08-03

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Sandoz获得欧洲委员会对生物仿制药Hyrimoz的批准

2018-07-30

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

EMA支持批准Amgen的Neulasta的第一个生物仿制药版本

2018-07-30

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

辉瑞生物仿制药Nivestym获FDA批准用于治疗中性粒细胞减少症

2018-07-25

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

Semin Arthritis Rheu：从原研药转为生物仿制药依那西普（SB4）的接受率和所涉及的社会学因素

2018-07-25

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-06-30

grace5701 (审核中...)

前往app查看评论内容

#生物仿制药#

欧盟通过Sandoz的Remicade生物仿制药Zessly

2018-05-26

科室
- - 订阅+
  - 更多科室
工具
服务